A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma

Required: BCMA cell surface expression (presence confirmed in patients with prior BCMA targeted therapy)

BCMA presence on the cell surface should be confirmed in patients who have been treated with prior BCMA targeted therapies.

Must have received: proteasome inhibitor

Patients with relapsed or refractory multiple myeloma who have been treated with a proteasome inhibitor

Must have received: IMiD

Patients with relapsed or refractory multiple myeloma who have been treated with...an IMiD

Must have received: anti-CD38 antibody

Patients with relapsed or refractory multiple myeloma who have been treated with...an anti-CD38 antibody

Cannot have received: BCMA targeted bispecific antibody

Prior treatment with a BCMA targeted bispecific antibody

Cannot have received: mezigdomide (mezigdomide)

Prior treatment with mezigdomide

Cannot have received: systemic anti-myeloma therapy

Exception: within ≤14 days

Systemic anti-myeloma therapy (including systemic steroids) within ≤14 days, or plasmapheresis within 7 days prior to the first dose of study drug.

Cannot have received: investigational drug

Exception: within 21 days or five half-lives (whichever is longer)

Use of an investigational drug within 21 days or five half-lives (whichever is longer) preceding the first dose of study drug.

Cannot have received: radiation therapy

Exception: within ≤14 days prior to study entry (bone lesions requiring radiation may be treated with limited [i.e., ≤ 25% of bone marrow in field] radiation therapy during this period)

Radiation therapy within ≤14 days prior to study entry

Cannot have received: live, attenuated vaccine or investigational vaccine

Exception: within 4 weeks before the first dose of study drug

Live, attenuated vaccine or investigational vaccine within 4 weeks before the first dose of study drug

Cannot have received: autologous stem cell transplant

Exception: within 60 days

Patients with a history of autologous stem cell transplant within 60 days

Cannot have received: allogeneic stem cell transplant

Exception: within 6 months prior to study enrollment

allogeneic stem cell transplant within 6 months prior to study enrollment

Cannot have received: CAR-T cell therapy

Exception: within 90 days prior to study enrollment

Patients who received CAR T therapy within 90 days prior to study enrollment